HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumors
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of ...
Jun 5, 2023
0
2